News
-
Cellceutix Approved By FDA To Proceed With Clinical Trials On Novel Cancer Drug
6/22/2012
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has completed the review of the Company's Investigational New Drug (IND) application for Kevetrin™, the Cellcetix's novel anti-cancer compound, and has yesterday informed Cellceutix that "we have completed the review of your submission, and have concluded that you may proceed with the proposed study."
- Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial 6/19/2012
-
Phase III Study: Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy
6/4/2012
Final results from PARAMOUNT, a Phase III study of ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY).
-
New Mobile App Helps Doctors Find Clinical Trials For Cancer Patients
6/1/2012
oday, Eli Lilly and Company (NYSE: LLY) launched a searchable clinical trial mobile application for oncology healthcare professionals.
-
BASi Adds Director Of Discovery Services, Expands West Lafayette Research Collaborative Opportunities
5/15/2012
BASi (Bioanalytical Systems Inc.) has named David Reynolds as its director of discovery services. Reynolds will oversee studies and staff of the company’s new Discovery Center at corporate headquarters in West Lafayette, Ind.
-
Galenea To Receive $6M From The Stanley Medical Research Institute To Progress Pro-Cognitive Drug Discovery And Development Program
4/26/2012
Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced that The Stanley Medical Research Institute (SMRI) will provide $6 million in an equity investment to support the development of Galenea's innovative pro-cognitive discovery program and the selection of a clinical candidate for the treatment of schizophrenia and other psychiatric disorders.
-
bioRASI To Sponsor The Evolution Summit 2012 In Chicago, USA
4/23/2012
bioRASI, a full service, global Contract Research Organization (CRO), will participate as a premier sponsor of the Annual Evolution Summit 2012 in Chicago, Illinois on April 30th -May 2nd. bioRASI will be showcasing its unique and powerful optimization strategies and solutions, designed to overcome the multifaceted challenges facing today's complex clinical development programs.
-
AMRI Signs Exclusive Option To License Its Tubulin Inhibitor Program For Cancer
4/9/2012
AMRI, a global contract healthcare services organization spanning the entire R&D continuum, announced recently that it has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC a translational drug development company led by industry veteran Barry A. Berkowitz, Ph.D., for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer.
-
ScinoPharm And National Health Research Institutes (NHRI) Announce Jointly Developed Diabetes Drug Approved For Phase I Clinical Trial
3/26/2012
ScinoPharm (TWSE1789), a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, today announced its CRO project, DBPR108, commissioned by the National Health Research Institutes (NHRI), has received approval by Taiwan and the U.S. Food and Drug Administration (FDA) to commence a Phase I clinical trial.
-
Celerion And Ricerca Biosciences Announce ‘The Biosimilars Alliance’ To Offer Clients A More Effective Development Path For Biosimilars
3/1/2012
Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”.